Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis (BAYnovation™)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
NovaBay Pharmaceuticals, Inc. Identifier:
First received: February 9, 2012
Last updated: March 26, 2014
Last verified: March 2014

The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis. Adults and children one year of age and older with adenoviral conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either NVC-422 or Vehicle. Six visits will be required for this study.

Condition Intervention Phase
Adenoviral Conjunctivitis
Drug: NVC-422 Ophthalmic Solution, 0.33%
Drug: Vehicle Ophthalmic Solution
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

Resource links provided by NLM:

Further study details as provided by NovaBay Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Sustained Clinical Cure [ Time Frame: Day 18 ] [ Designated as safety issue: No ]

Estimated Enrollment: 450
Study Start Date: May 2012
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NVC-422 Ophthalmic Solution, 0.33%
Dosed for 10 days
Drug: NVC-422 Ophthalmic Solution, 0.33%
Placebo Comparator: Vehicle Ophthalmic Solution
Dosed for 10 days
Drug: Vehicle Ophthalmic Solution


Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signs and symptoms of viral conjunctivitis in at least one eye for 3 days or less
  • Bulbar conjunctival injection
  • Other inclusion criteria per protocol

Exclusion Criteria:

  • Presence of subepithelial infiltrates (SEIs) at the Day 1 visit in either eye
  • A suspected bacterial, fungal, herpes, Chlamydia or Acanthamoeba co-infection, based on clinical observation
  • Other exclusion criteria per protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01532336

  Hide Study Locations
United States, California
Glendale, California, United States, 91205
Los Angeles, California, United States, 90048
Petaluma, California, United States, 94954
San Diego, California, United States, 92115
United States, Florida
Fort Myers, Florida, United States, 33901
Jacksonville Beach, Florida, United States, 32250
Tampa, Florida, United States, 33603
United States, Georgia
Albany, Georgia, United States, 31701
United States, Hawaii
Kailua, Hawaii, United States, 96734
United States, Illinois
Glenview, Illinois, United States, 60026
Peoria, Illinois, United States, 61615
United States, Kansas
Shawnee Mission, Kansas, United States, 66204
United States, Kentucky
Hazard, Kentucky, United States, 41701
United States, Massachusetts
Winchester, Massachusetts, United States, 01890
United States, Missouri
Kansas City, Missouri, United States, 64154
St. Louis, Missouri, United States, 63131
United States, New York
Hicksville, New York, United States, 11801
Rockville Centre, New York, United States, 11570
United States, North Carolina
Asheville, North Carolina, United States, 28803
High Point, North Carolina, United States, 27262
Winston-Salem, North Carolina, United States, 27101
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States, 15206
United States, South Carolina
Charleston, South Carolina, United States, 29414
Spartanburg, South Carolina, United States, 29306
Recife, PE, Brazil, 50070-040
Rio de Janeiro, RJ, Brazil, 21941-913
Porto Alegre, RS, Brazil, 90035-903
Joinville, SC, Brazil, 89201-010
Sao Paulo, SP, Brazil, 04023-062
Sao Paulo, SP, Brazil, 01221-020
Sao Paulo, SP, Brazil, 04502-001
Sorocaba, SP, Brazil, 18031-060
Hyderabad, Andhra Pradesh, India, 500 034
Hyderabad, Andhra Pradesh, India, 500 096
Ahmadabad, Gujarat, India, 380 016
Surat, Gujarat, India, 395 001
Bangalore, Karnataka, India, 560 054
Bangalore, Karnataka, India, 560 010
Thiruvanathapuram, Kerala, India, 695 011
Mumbai, Maharashtra, India, 400 004
Mumbai, Maharashtra, India, 400 020
Mumbai, Maharashtra, India, 400 602
Mumbai, Maharashtra, India, 400 080
Daryaganj, New Dehli, India, 110 002
Bikaner, Rajasthan, India, 334 001
Jaipur, Rajasthan, India, 302 015
Jaipur, Rajasthan, India, 302 004
Chennai, Tamil Nadu, India, 600 010
Salem, Tamil Nadu, India, 636 004
Kolkata, West Bengal, India, 700 073
New Dehli, India, 110 608
Vishakhapatnam, India, 530 013
Sri Lanka
Colombo, Sri Lanka, 01000
Colombo, Sri Lanka, 11010
Colombo, Sri Lanka
Kalubowila, Sri Lanka, 10350
Negombo, Sri Lanka, 11500
Nugegoda, Sri Lanka, 10250
Sponsors and Collaborators
NovaBay Pharmaceuticals, Inc.
Study Director: David Stroman, Ph.D. NovaBay Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: NovaBay Pharmaceuticals, Inc. Identifier: NCT01532336     History of Changes
Other Study ID Numbers: CL1104, BAYnovation
Study First Received: February 9, 2012
Last Updated: March 26, 2014
Health Authority: United States: Food and Drug Administration
Brazil: National Health Surveillance Agency
India: Drugs Controller General of India
Sri Lanka: Cosmetics Devices & Drugs Regulatory Authority

Keywords provided by NovaBay Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Conjunctival Diseases
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2014